Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2016

01-04-2016 | Review

Inter-organ communication and regulation of beta cell function

Authors: Mehboob A. Hussain, Elina Akalestou, Woo-jin Song

Published in: Diabetologia | Issue 4/2016

Login to get access

Abstract

The physiologically predominant signal for pancreatic beta cells to secrete insulin is glucose. While circulating glucose levels and beta cell glucose metabolism regulate the amount of released insulin, additional signals emanating from other tissues and from neighbouring islet endocrine cells modulate beta cell function. To this end, each individual beta cell can be viewed as a sensor of a multitude of stimuli that are integrated to determine the extent of glucose-dependent insulin release. This review discusses recent advances in our understanding of inter-organ communications that regulate beta cell insulin release in response to elevated glucose levels.
Literature
1.
Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434–3438CrossRefPubMedPubMedCentral
2.
Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC (1990) Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. Endocrinology 126:2164–2168CrossRefPubMed
3.
4.
Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616–619CrossRefPubMedPubMedCentral
5.
Brown JC (1974) Candidate hormones of the gut. 3. Gastric inhibitory polypeptide (GIP). Gastroenterology 67:733–734PubMed
6.
Brown JC, Cleator IG, Dryburgh JR, Pederson RA, Schubert H (1974) The physiology and pathophysiology of gastric inhibitory polypeptide (GIP) and motilin. Verh Dtsch Ges Inn Med 80:377–380PubMed
7.
Cataland S, Crockett SE, Brown JC, Mazzaferri EL (1974) Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man. J Clin Endocrinol Metab 39:223–228CrossRefPubMed
8.
Turner DS, Etheridge L, Jones J et al (1974) The effect of the intestinal polypeptides, IRP and GIP, on insulin release and glucose tolerance in the baboon. Clin Endocrinol (Oxf) 3:489–493CrossRef
9.
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705CrossRefPubMed
10.
11.
Smith EP, An Z, Wagner C et al (2014) The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab 19:1050–1057CrossRefPubMedPubMedCentral
12.
Svendsen B, Pedersen J, Albrechtsen NJ et al (2015) An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology 156:847–857CrossRefPubMed
13.
Wice BM, Wang S, Crimmins DL et al (2010) Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J Biol Chem 285:19842–19853CrossRefPubMedPubMedCentral
14.
Zhang S, Hyrc K, Wang S, Wice BM (2012) Xenin-25 increases cytosolic free calcium levels and acetylcholine release from a subset of myenteric neurons. Am J Physiol Gastrointest Liver Physiol 303:G1347–G1355CrossRefPubMedPubMedCentral
15.
Chowdhury S, Reeds DN, Crimmins DL et al (2014) Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Am J Physiol Gastrointest Liver Physiol 306:G301–G309CrossRefPubMedPubMedCentral
16.
Nasteska D, Harada N, Suzuki K et al (2014) Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63:2332–2343CrossRefPubMed
17.
Campbell JE, Ussher JR, Mulvihill EE et al (2016) TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med 22:84–90CrossRefPubMed
18.
Lilavivathana U, Campbell RG, Brodows RG (1978) Control of insulin secretion during fasting in man. Metabolism 27:815–821CrossRefPubMed
19.
20.
Prado CL, Pugh-Bernard AE, Elghazi L, Sosa-Pineda B, Sussel L (2004) Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc Natl Acad Sci U S A 101:2924–2929CrossRefPubMedPubMedCentral
21.
Wierup N, Svensson H, Mulder H, Sundler F (2002) The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 107:63–69CrossRefPubMed
22.
Wierup N, Yang S, McEvilly RJ, Mulder H, Sundler F (2004) Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J Histochem Cytochem 52(3):301–310CrossRefPubMed
23.
24.
Li RL, Sherbet DP, Elsbernd BL, Goldstein JL, Brown MS, Zhao TJ (2012) Profound hypoglycemia in starved, ghrelin-deficient mice is caused by decreased gluconeogenesis and reversed by lactate or fatty acids. J Biol Chem 287:17942–17950CrossRefPubMedPubMedCentral
25.
McFarlane MR, Brown MS, Goldstein JL, Zhao TJ (2014) Induced ablation of ghrelin cells in adult mice does not decrease food intake, body weight, or response to high-fat diet. Cell Metab 20:54–60CrossRefPubMedPubMedCentral
26.
Barnett BP, Hwang Y, Taylor MS et al (2010) Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science 330:1689–1692CrossRefPubMedPubMedCentral
27.
Tang G, Wang Y, Park S et al (2012) Go2 G protein mediates galanin inhibitory effects on insulin release from pancreatic beta cells. Proc Natl Acad Sci U S A 109:2636–2641CrossRefPubMedPubMedCentral
28.
Wang Y, Park S, Bajpayee NS, Nagaoka Y, Boulay G, Birnbaumer L, Jiang M (2011) Augmented glucose-induced insulin release in mice lacking G(o2), but not Go1 or Gi proteins. Proc Natl Acad Sci U S A 108:1693–1698CrossRefPubMedPubMedCentral
29.
Hussain MA, Song WJ, Wolfe A (2015) There is Kisspeptin—and there is Kisspeptin. Trends Endocrinol Metab 26:564–572CrossRefPubMed
30.
31.
Kieffer TJ, Habener JF (2000) The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab 278:E1–E14PubMed
32.
Kieffer TJ, Heller RS, Habener JF (1996) Leptin receptors expressed on pancreatic beta-cells. Biochem Biophys Res Commun 224:522–527CrossRefPubMed
33.
Kieffer TJ, Heller RS, Leech CA, Holz GG, Habener JF (1997) Leptin suppression of insulin secretion by the activation of ATP-sensitive K+ channels in pancreatic beta-cells. Diabetes 46:1087–1093CrossRefPubMedPubMedCentral
34.
Morioka T, Asilmaz E, Hu J et al (2007) Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 117:2860–2868CrossRefPubMedPubMedCentral
35.
Seufert J, Kieffer TJ, Habener JF (1999) Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice. Proc Natl Acad Sci U S A 96:674–679CrossRefPubMedPubMedCentral
36.
Seufert J, Kieffer TJ, Leech CA et al (1999) Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 84:670–676PubMedPubMedCentral
37.
Soedling H, Hodson DJ, Andrianssens AE et al (2015) Limited impact on glucose homeostasis of leptin receptor deletion from insulin- or proglucagon-expressing cells. Mol Metab 4:619–630CrossRefPubMedPubMedCentral
38.
Ye R, Holland WL, Gordillo R et al (2014) Adiponectin is essential for lipid homeostasis and survival under insulin deficiency and promotes beta-cell regeneration. Elife 3:e03851PubMedCentral
39.
Ye R, Wang M, Wang QA, Scherer PE (2015) Adiponectin-mediated antilipotoxic effects in regenerating pancreatic islets. Endocrinology 156:2019–2028CrossRefPubMed
40.
Cantley J (2014) The control of insulin secretion by adipokines: current evidence for adipocyte–beta cell endocrine signalling in metabolic homeostasis. Mamm Genome 25:442–454CrossRefPubMed
41.
Wei J, Karsenty G (2015) An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord 16:93–98CrossRefPubMed
42.
Oury F, Ferron M, Huizhen W et al (2013) Osteocalcin regulates murine and human fertility through a pancreas–bone–testis axis. J Clin Invest 123:2421–2433CrossRefPubMedPubMedCentral
43.
44.
Clemens TL, Karsenty G (2011) The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res 26:677–680CrossRefPubMed
45.
46.
47.
Wei J, Hanna T, Suda N, Karsenty G, Ducy P (2014) Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a. Diabetes 63:1021–1031CrossRefPubMedPubMedCentral
48.
Fulzele K, Riddle RC, DiGirolamo DJ et al (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142:309–319CrossRefPubMedPubMedCentral
49.
Wei J, Ferron M, Clarke CJ et al (2014) Bone-specific insulin resistance disrupts whole-body glucose homeostasis via decreased osteocalcin activation. J Clin Invest 124:1–13CrossRefPubMed
50.
Abdallah BM, Ditzel N, Laborda J, Karsenty G, Kassem M (2015) DLK1 regulates whole-body glucose metabolism: a negative feedback regulation of the osteocalcin–insulin loop. Diabetes 64:3069–3080CrossRefPubMed
51.
Ducy P, Amling M, Takeda S et al (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207CrossRefPubMed
52.
Takeda S, Elefteriou F, Levasseur R et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305–317CrossRefPubMed
53.
Bartell SM, Rayalam S, Ambati S et al (2011) Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. J Bone Miner Res 26:1710–1720CrossRefPubMed
54.
Kajimura D, Lee HW, Riley KJ et al (2013) Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab 17:901–915CrossRefPubMedPubMedCentral
55.
Kondegowda NG, Fenutria R, Pollack IR et al (2015) Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of nf-kappab ligand pathway. Cell Metab 22:77–85CrossRefPubMed
56.
Ellingsgaard H, Hauselmann I, Schuler B et al (2011) Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17:1481–1489CrossRefPubMedPubMedCentral
57.
Bouzakri K, Plomgaard P, Berney T, Donath MY, Pedersen BK, Halban PA (2011) Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60:1111–1121CrossRefPubMedPubMedCentral
58.
Hanchang W, Semprasert N, Limjindaporn T, Yenchitsomanus PT, Kooptiwut S (2013) Testosterone protects against glucotoxicity-induced apoptosis of pancreatic beta-cells (INS-1) and male mouse pancreatic islets. Endocrinology 154:4058–4067CrossRefPubMed
59.
Kooptiwut S, Hanchang W, Semprasert N, Junking M, Limjindaporn T, Yenchitsomanus PT (2015) Testosterone reduces AGTR1 expression to prevent beta-cell and islet apoptosis from glucotoxicity. J Endocrinol 224:215–224CrossRefPubMed
60.
Le May C, Chu K, Hu M et al (2006) Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 103:9232–9237CrossRefPubMedPubMedCentral
61.
62.
Kilic G, Alvarez-Mercado AI, Zarrouki B et al (2014) The islet estrogen receptor-alpha is induced by hyperglycemia and protects against oxidative stress-induced insulin-deficient diabetes. PLoS One 9:e87941CrossRefPubMedPubMedCentral
63.
Liu S, Le May C, Wong WP et al (2009) Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58:2292–2302CrossRefPubMedPubMedCentral
64.
65.
Tiano JP, Delghingaro-Augusto V, Le May C et al (2011) Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents beta cell failure in rodent models of type 2 diabetes. J Clin Invest 121:3331–3342CrossRefPubMedPubMedCentral
66.
Wong WP, Tiano JP, Liu S et al (2010) Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A 107:13057–13062CrossRefPubMedPubMedCentral
67.
Navarro G, Allard C, Xu W, Mauvais-Jarvis F (2015) The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) 23:713–719CrossRef
68.
69.
Kim K, Oh CM, Ohara-Imaizumi M et al (2015) Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state. Endocrinology 156:444–452CrossRefPubMedPubMedCentral
70.
Logie JJ, Denison FC, Riley SC et al (2012) Evaluation of kisspeptin levels in obese pregnancy as a biomarker for pre-eclampsia. Clin Endocrinol (Oxf) 76:887–893CrossRef
71.
Ahren B (2000) Autonomic regulation of islet hormone secretion—implications for health and disease. Diabetologia 43:393–410CrossRefPubMed
72.
Edvell A, Lindstrom P (1998) Vagotomy in young obese hyperglycemic mice: effects on syndrome development and islet proliferation. Am J Physiol 274:E1034–E1039PubMed
73.
74.
Kiba T (2004) Relationships between the autonomic nervous system and the pancreas including regulation of regeneration and apoptosis: recent developments. Pancreas 29:e51–e58CrossRefPubMed
75.
Kiba T, Tanaka K, Numata K, Hoshino M, Misugi K, Inoue S (1996) Ventromedial hypothalamic lesion-induced vagal hyperactivity stimulates rat pancreatic cell proliferation. Gastroenterology 110:885–893CrossRefPubMed
76.
77.
Rodriguez-Diaz R, Dando R, Jacques-Silva MC et al (2011) Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans. Nat Med 17:888–892CrossRefPubMedPubMedCentral
78.
Gilon P, Henquin JC (2001) Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 22:565–604PubMed
79.
Satin LS, Kinard TA (1998) Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit? Endocrine 8:213–223CrossRefPubMed
80.
Duttaroy A, Zimliki CL, Gautam D, Cui Y, Mears D, Wess J (2004) Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 53:1714–1720CrossRefPubMed
81.
Gautam D, Han SJ, Hamdan FF et al (2006) A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 3:449–461CrossRefPubMed
82.
Guettier JM, Gautam D, Scarselli M et al (2009) A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A 106:19197–19202CrossRefPubMedPubMedCentral
83.
Shi X, Zhou F, Li X et al (2013) Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 18:86–98CrossRefPubMedPubMedCentral
84.
Liu C, Lee S, Elmquist JK (2014) Circuits controlling energy balance and mood: inherently intertwined or just complicated intersections? Cell Metab 19:902–909CrossRefPubMedPubMedCentral
85.
Ahren B, Ericson LE, Lundquist I, Loren I, Sundler F (1981) Adrenergic innervation of pancreatic islets and modulation of insulin secretion by the sympatho-adrenal system. Cell Tissue Res 216:15–30CrossRefPubMed
86.
Borden P, Houtz J, Leach SD, Kuruvilla R (2013) Sympathetic innervation during development is necessary for pancreatic islet architecture and functional maturation. Cell Rep 4:287–301CrossRefPubMedPubMedCentral
87.
Tan Z, Fogel R, Jiang C, Zhang X (2004) Galanin inhibits gut-related vagal neurons in rats. J Neurophysiol 91:2330–2343CrossRefPubMed
Metadata
Title
Inter-organ communication and regulation of beta cell function
Authors
Mehboob A. Hussain
Elina Akalestou
Woo-jin Song
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3862-7

Other articles of this Issue 4/2016

Diabetologia 4/2016 Go to the issue

Article

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes

Letter

The pancreas in humans with and without diabetes

Article

Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans

Article

Serotonin (5-HT) receptor 2b activation augments glucose-stimulated insulin secretion in human and mouse islets of Langerhans

Article

Long-term cardiovascular outcomes in type 1 diabetic patients after simultaneous pancreas and kidney transplantation compared with living donor kidney transplantation

Article

Adipose tissue transcriptomics and epigenomics in low birthweight men and controls: role of high-fat overfeeding
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits